Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extending omalizumab treatment intervals in chronic spontaneous urticaria (EXOTIC)
2023-506187-14-00Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of omalizumab in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Absolute difference in average urticaria control test (UCT) score between treatment arms at week 36. Started Nov 2023; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2023-506187-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506187-14-00.